Diversify Wealth Management LLC Grows Position in Bristol Myers Squibb Company $BMY

Diversify Wealth Management LLC grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 191.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,139 shares of the biopharmaceutical company’s stock after acquiring an additional 21,775 shares during the quarter. Diversify Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $1,908,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. Bayban purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 4.0%

BMY opened at $56.98 on Wednesday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The business has a 50 day simple moving average of $56.80 and a two-hundred day simple moving average of $57.69. The firm has a market capitalization of $116.37 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 0.17 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the company earned $1.80 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb’s payout ratio is 70.79%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.25.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.